Konica Minolta acquires Invicro and expands precision medicine business

Invicro (MA, USA), a CRO that provides imaging services from early phase discovery to late phase clinical trials, has been acquired by Konica Minolta (Tokyo, Japan). Through this move, Konica Minolta hopes to accelerate their precision medicine platform, discovering new therapeutics and technologies.

The precision medicine platform aims to increase an individual’s quality of life by eliminating ineffective treatments whilst at the same time lowering the cost and time involved in pharmaceutical drug discovery. The new collaboration is stated to cause no change to Invicro’s management structure with the business operating as usual.

Jack Hoppin, Co-Founder and CEO of Invicro commented: “We are a quantitative biomarker company. Whether in medical imaging or digital pathology, we seek to distill complex biological measurements into straightforward decision criteria at each stage of pharmaceutical development.

“Konica Minolta is the ideal partner to accelerate the impact of the informatics platform we have developed and deployed over the past decade. The prospect of working with Konica Minolta and their recently acquired Ambry team on the translation of precision medicine innovations from research trials to clinical offerings is truly inspiring. We’re excited to be a part of the new disruption in the industry being assembled by Konica Minolta.”

Kunihiro Koshizuka, Senior Executive Officer, CTO, Konica Minolta concluded: “Invicro and Konica Minolta have some of the most powerful digital imaging and data management tools available to biomedical researchers and clinicians.

“The combination of our tools and expertise creates unparalleled cutting-edge capabilities that we believe are unmatched in the business. While research and development expenses are increasing, the number of medicines approved for use is slow and improving the productivity of new drug development is an important issue for the pharmaceutical industry. We look to offer cost-effective solutions to these problems that pharmaceutical companies face through this new platform.”

Source: www.konicaminolta.com/about/releases/2017/0925_01_01.html